We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Study Identifies Optimal Blood Tests for Detection and Treatment of Early Stage Alzheimer’s

By LabMedica International staff writers
Posted on 02 Dec 2022
Print article
Image: A study has identified optimal blood tests for development of new therapies of Alzheimer’s disease (Photo courtesy of Pexels)
Image: A study has identified optimal blood tests for development of new therapies of Alzheimer’s disease (Photo courtesy of Pexels)

A new study has identified which blood tests are best at detecting Alzheimer’s disease during the earliest stages, and also another blood test that is optimal for detecting relevant treatment effects. These findings will speed up the development of new therapies that can slow down the disease progression.

The study led by researchers at Lund University (Lund, Sweden) and University of Gothenburg (Gothenburg, Sweden) looked at several newly development blood tests for Alzheimer’s disease pathology and neurodegeneration in 575 individuals from the BioFINDER cohort. In 242 participants, the plasma tests were repeated for up to six years, along with cognitive testing and magnetic resonance imaging. The study revealed that multiple blood biomarkers, namely phospho-tau231 and Aβ42/40, were sufficient in identifying Alzheimer’s disease pathology, even in participants with no symptoms and thus, could be used as strategy to select the correct individuals for novel disease modifying trials – a task which currently requires expensive molecular imaging technique or lumbar punctures.

Yet, over the six years tested, it was shown that only phospho-tau217 was related to Alzheimer’s disease pathology, a decline in cognitive performance and increased brain atrophy typical of incipient Alzheimer’s. Therefore, phospho-tau217 will be an ideal marker for detection of relevant disease-modifying effects of novel interventions. An important aspect of this study was that p-tau217 was able to monitor such changes in pathology and cognition at very early stages of the disease process. The study has large implications on the use of blood test in the recently reported anti-Aβ trials.

“Distinctive blood tests may be optimal for the identification of Alzheimer’s pathology or for monitoring of disease progression and therefore have different roles in clinical trials,” explained Dr. Nicholas Ashton from the University of Gothenburg, first author of the research study. “This study has shown that phospho-tau217 is uniquely placed to be an optimal test for monitoring patients in both a clinical setting and a trial setting because of its longitudinal association with Alzheimer’s development.”

“Besides improving the design of clinical trials, the novel blood tests will revolutionize the diagnoses of early stages of Alzheimer’s disease,” added Oskar Hansson. “Further, phospoho-tau217 might be used in the future to monitor the response in individual patients to disease-modifying therapies in clinical practice.”

Related Links:
Lund University
University of Gothenburg

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.